Dr. Wabnitz studied biology in Goettingen and Hannover (Germany). He obtained his PhD from the Leibniz University of Hannover for his research on lung cancer models. Currently, Dr. Wabnitz has more than nine years of professional experience in industrial drug discovery and development. As Head Pharmacology at InterMed Discovery GmbH (IMD; Dortmund, Germany) Dr. Wabnitz is responsible for pharmacological research in all fields of IMD´s activities, as well as for IMD´s pharmacological pipeline projects.

Before joining IMD in 2007, Dr. Wabnitz oversaw toxicology within the early projects pipeline at Schwarz Pharma (UCB Group). Prior to this engagement Dr. Wabnitz worked for Ingenium Pharmaceuticals AG (Munich), where, as Director Kinase Inhibitor Projects, he was responsible for the interdisciplinary drug discovery process regarding kinase inhibitors.